1 Introduction Epithelial ovarian cancer (EOC) is the fifth most common cause of female cancer death in the developed world. It affects every year 21,750 women in the USA of whom 13,940 will die of the disease (1). Despite aggressive surgeries and combined chemotherapies, the prognosis remains worrisome. The reason for this high mortality rate is the late presentation, meaning that more than 70% of EOC are diagnosed at stage III or IV with a 5-year Overall Survival of approximately 15-30%.
